Author + information
- Poonam Velagapudi,
- Mohit Turagam,
- Dhaval Kolte,
- Sahil Khera,
- Herbert Aronow,
- Jane Leopold and
- J. Abbott
Background: Intramyocardial injection of human CD34+ cells may improve outcomes in patients with chronic refractory angina not amenable to revascularization or standard medical therapy. We performed a meta-analysis to evaluate the effect of this therapy in patients with refractory angina.
Methods: A comprehensive literature search using the terms: stem cells, CD34+cells and refractory angina was performed in Pubmed, Ebsco and Google scholar databases. Three eligible randomized trials including 212 patients (placebo 89, CD34+ 179) were included. Dose of auto-CD34+ cells ranged from 1 × 105 (low dose) to 5 × 105 (high dose) cells/kg. Follow-up ranged from 3–24 months.
Results: Baseline characteristics were similar between groups across all studies. The risk of all-cause mortality was reduced, angina severity improved and exercise tolerance increased in the CD34+ compared with control group (Fig 1,2,3). However, there was no significant difference in the risk of myocardial infarction (MI) [HR 1.31, 95% CI (0.61–2.78), p=0.49] and stroke [HR 0.39, 95% CI (0.04–3.38), P=0.39] between groups. The Cochrane q-statistic demonstrated low degree of heterogeneity (I2 =0%) among studies for all clinical outcomes except angina frequency I2=94%).
Conclusions: In a meta-analysis, intra-myocardial CD34+ cell therapy was associated with significantly decreased risk of mortality, and anginal frequency, and increased exercise tolerance compared with placebo. No significant difference in MI and stroke was noted.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Interventional Cardiology: Translation and Pre-Clinical Research
Abstract Category: 25. Interventional Cardiology: Translation and Pre-clinical Research
Presentation Number: 1116-185
- 2017 American College of Cardiology Foundation